Clinical Trials
60 trialsNCT04722172 2026-06-04
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04765111 2026-05-20
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05495464 2026-05-20
A Pilot "Window-3" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04941716 2026-05-18
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT07582159 2026-05-12
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
City of Hope Medical Center
Phase 2 Not yet recruiting
NCT04657094 2026-05-06
Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04978584 2026-05-05
Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04546620 2026-04-30
REMoDL-A
University Hospital Southampton NHS Foundation Trust
Phase 2 Active not recruiting
NCT03863184 2026-04-28
Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL
Weill Medical College of Cornell University
Phase 2 Active not recruiting
NCT03623373 2026-04-21
Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma
Washington University School of Medicine
Phase 2 Completed
NCT04189757 2026-04-16
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04169737 2026-04-14
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04560322 2026-04-13
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Massachusetts General Hospital
Phase 2 Recruiting
NCT04646395 2026-04-06
Study of Acalabrutinib and Tafasitamab in MZL Patients
International Extranodal Lymphoma Study Group (IELSG)
Phase 2 Active not recruiting
NCT05388006 2026-03-25
Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Recruiting
NCT05256641 2026-03-10
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT04624633 2026-02-25
Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05336812 2026-02-19
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT03946878 2026-02-17
Venetoclax and Acalabrutinib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03580928 2026-02-13
AVO
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03516617 2026-02-09
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Recruiting
NCT04883437 2026-02-09
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Emory University
Phase 2 Recruiting
NCT04624906 2026-02-04
BRAWM
Sunnybrook Health Sciences Centre
Phase 2 Active not recruiting
NCT05583149 2026-01-29
Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04855695 2026-01-21
Avo In R/R And Previously Untreated MCL
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT07014917 2026-01-06
ESR-23-22182
University of Cincinnati
Phase 2 Recruiting
NCT06054776 2026-01-05
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT04604067 2025-12-30
Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
Swiss Cancer Institute
Phase 2 Active not recruiting
NCT04505254 2025-12-26
Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06757647 2025-12-16
Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT07052695 2025-12-15
Mosunetuzumab for CLL MRD Clearance
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT05065554 2025-12-05
ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04484012 2025-11-26
Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center
Phase 2 Recruiting
NCT06958705 2025-11-25
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Recruiting
NCT03128879 2025-11-21
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05943496 2025-11-06
Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
OHSU Knight Cancer Institute
Phase 1 Recruiting
NCT04198922 2025-11-05
Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease
Fred Hutchinson Cancer Center
Phase 2 Active not recruiting
NCT04257578 2025-10-08
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
University of Washington
Phase 1/2 Active not recruiting
NCT05971251 2025-10-01
Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia
University of Alabama at Birmingham
Phase 1 Active not recruiting
NCT05197192 2025-08-17
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
German CLL Study Group
Phase 3 Recruiting
NCT04883749 2025-06-08
CLL-Frail
German CLL Study Group
Phase 2 Completed
NCT06846489 2025-06-03
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma
Sun Yat-sen University
Phase 2 Recruiting
NCT04189952 2025-05-31
Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma
University of Miami
Phase 2 Terminated
NCT04685915 2025-05-22
Copanlisib Plus Ibrutinib or Acalabrutinib in R/R CLL
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT04402138 2025-05-13
Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma
SCRI Development Innovations, LLC
Phase 2 Completed
NCT05004064 2025-04-09
CARAMEL
University College, London
Phase 2 Recruiting
NCT04566887 2025-02-18
Acalabrutinib With R-CHOP in Previously Untreated Mantle Cell Lymphoma
University Health Network, Toronto
Phase 2 Recruiting
NCT03787264 2024-12-30
CLL2-BAAG
German CLL Study Group
Phase 2 Completed
NCT04783415 2024-12-02
Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03788291 2024-09-26
Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
University of Rochester
Phase 2 Completed